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Abstract
Spinal Muscular Atrophy (SMA) is an autosomal recessive disease affecting the anterior hom cells of
the spinal cord. The diagnosis is usually based on the clinical presentation with or without muscle
biopsy and the molecular detection of mutation in the SMN I gene. There have been a few reported
cases of SMA with central nervous system involvement, but these were without genetic diagnoses. We
report a Malay girl with genetically confirmed SMA complicated by epilepsy. She first presented with
motor weakness at the age of 17 months and recurrent seizures a month later. The molecular genetic
analysis ofher SMN gene showed homozygous deletion of exon 7 and 8 of the SMN1 gene. The seizure
responded well to carbamazepine. To the best of our knowledge, this is the first case of genetically
confinned Malay SMA patient with an association with epilepsy.
INTRODUCTION
Spinal Muscular Atrophy (SMA) is a common
neuromuscular disorder resulting from the
degeneration of anterior hom cells of the spinal
cord. It is clinically classified into 3 sub-types
based on the' age of onset and severity; type 1 is
the severe fonn with onset before the age of 6
months, and the patient is unable to sit without
support; type 2 is the intermediate form with
onset before 18 months, and the patient is unable
to stand or walk without aid; and type 3 is the
mildest form with age of onset after 18 months,
and the patient is able to stand and walk. 1 The
genes for all 3 subtypes of SMA have been
mapped to chromosome 5q13. So far, two major
SMA-related genes have been identified in this
region; the Neuronal Apoptosis Inhibitory Protein
(NAIP) gene2 and the Survival Motor Neuron
(SMN) gene. 3 According to the previous reports,
the SMN 1 gene is homozygously deleted in
more than 90% of SMA patients 3,4,5,6 and
deleteriously mutated in the remainder.7,8.9,lO This
provide strong evidence that the SMN 1 gene is
responsible for SMA.
There have been a few reported cases of SMA
with central nervous system involvement, but
most were without genetic diagnoses. One SMA
patient with central nervous system involvement
was reported in Japan. ll We report a Malay girl
with genetically confmned SMA and complicated
by epilepsy.
, CASE REPORT
Our patient was a 6 year old girl, born to healthy
non-consanguineous parents. There was no family
history ofneurological illness. She first presented
at the age of 17 months with broad-based unsteady
gait and walked by holding on to a chair. Two
months later, her motor function regressed and
she could neither stand nor lift up her legs. Her
motor function remained static and on the latest
review, at six years of age, she could only sit
unsupported and cannot weight bear. She uses
her upper limbs well and move around by bottom-
shuffling. On examination, she was a non-
dysmorphic talkative child. Her lower limbs were
hypotonic with muscle power of 2/5 on both
sides, while her upper limbs have a power of 4/5.
Knee jerk and ankle jerk reflexes were absent on
both her lower limbs but preserved at her upper
limbs. Her sensory system was normal.
Routine needle EMG showed spontaneous
fibrillation at rest with denervation patterns. The
common peroneal motor nerve conduction was
normal. The parents did not consent to muscle
biopsy. The molecular genetic analysis of her
SMN gene showed homozygous deletion of exon
7 and 8 of the SMN1 gene.
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She was diagnosed as SMA based on her
clinical presentation, the molecular analysis of
her SMNI gene and the supportive evidence
from her EMG and nerve conduction study.
The clinical course of her disease were further
complicated by epilepsy. Her first episode of
.seizure occurred at the age of 18 ~onths, which
was preceded by fever. There was up-rolling of
both eyeballs, drooling of saliva and tonic-clonic
movements of both upper limbs, lasting a few
minutes. There was no evidence of central nervous
system infection. Subsequently, there were
frequent episodes of seizures, which were usually,
but not always, precipitated by fever, requiring
multiple hospital admissions. Each hospital
admission lasted a few days before seizure control
could be achieved. She was given carbamazepine
l50mg per day resulting in adequate seizure
control. Her EEG was normal.
DISCUSSION
This is. a case of type 3 SMA based on clinical
presentation, subsequently confrrmed by genetic
analysis, and complicated by epilepsy. The
association between SMA and central nervous
system abnOImality has been reported by Higashi
K et.al. ll They described a 37 years old woman
who first presented with SMA at the age of 12
years and epilepsy at the age of 33. This
association can be postulated by the extent of
distribution of the SMN gene, which is found not
only in spinal cord but also in the brain. The
central nervous system involvement detected in
their patient could therefore be related to the loss
of this SI\.1N gene function in the brain, besides
the possibility of coincidental association of SMA
and epilepsy. This postulation could also be
extended to our patient who differs from theirs
only in the age of onset of her SMA and epilepsy.
An association between a variant of SMA and
epilepsy has been made by Haliloglu G et.a. 12 •
They reported 4 patients from two families
affected by severe and progressive myoclonic
epilepsy and SMA. They found an association
between myoclonic epilepsy and non-5q-SMA,
which represents a separate clinical and genetic
entity from the 5q-SMA. Our patient is a typical
5q-SMA with epilepsy, caused by a mutation in
the SMNI gene, while the non-5q-SMA is not.
The primary genetic defect of this SMA variant is
still unknown.
Our patient has responded well to the anti
epileptic drug carbamazepine. Another long-term
epileptic drug that is commonly used is sodium
valproate. A recent study by Brichta L et.al 13 on
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SMA patient treated with sodium valproate found
an increased in the full-length transcript from the
SMN2 gene. Their findings has opened the
exciting perspective for a first causal therapy of
inherited disease by elevating the SMN2
transcription level and restoring it's correct
splicing. In future, should there be a breakthrough
fits in our patient, a change to sodium valproate
could therefore be beneficial not just to her
epilepsy t but also to her SMA.
To the best of our knowledge, this is the first
case of genetically confirmed Malay SMA patient
with an association with epilepsy.
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Fig. 3: NAIP gene exon 5.
Deletion of exon 5 of NAIP gene is seen in Lane 2 and 3.
Lane M: Ladder
Lane 1: Healthy control
Lane 2: Patient 1
Lane 3: Patient 2
Lane 4: Patient 3
Lane 5: peR control (water)
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Discussion
We identified homozygous deletion of SMNI exon 7
and 8 in all our 3 SMA patients. These results
correspond to the findings of Levebvre et a)1 and Erdem
et aF who found more than 90% of their patients carried
the homozygous deletion of SMNI exon 7 and 8.
Homozygous deletion of NAIP exon 5 is detected in
only our type 1 patients but not in the type 3 patient.
This finding is similar to Roy et aP and Akutsu et al) and
who have demonstrated a correlation between deletion
of the NAIP gene and the severity of SMA.
To the best of our knowledge, these are the first SMA
cases diagnosed at the molecular level in Malaysia.
However, further larger studies need to be done before
we can make any firm conclusion regarding the SMN
and NAIP genes in the Malay population.
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Survival Motor Neuron and Neuronal Apoptosis Inhibitory Protein Genes
and 2 had a severe form (SMA type 1) while Patient 3
had a mild form (SMA type 3). Genomic DNA was
extracted from 3 ml of whole blood from the patients
after obtaining their informed consent. The analysis for
the SMN genes was perfofmed according to the method
of van der Steege et a14• PCR was done to amplify the
gene using primer sets for SMN exon 7 and another
primer set for exon 8. To discriminate between the
SMNI and SMN2 gene products, the PCR product was
then subjected to Dra I and Dde 1 restriction enzyme
treatment. Dra I restriction enzyme digests only the
exon 7 of SMN2 gene products, and not the SMNI gene
products, while Ddel restriction enzyme digests only
the exon 8 of SMN 2 and not the SMN 1 gene products.
The final products were electrophoresed in 3% agarose
gel and visualized by ethidium bromide staining. PCR
amplification of the NAIP gene was performed
according to the method of Roy et a13. peR was done
to amplify NAIP exon 5. The peR products were
electrophoresed in 3% agarose gels and visualized by
ethidium bromide staining.
Results
In control samples, non-digested and digested products
of SMNI and SMN2 exons 7 and 8 were seen on the gel
(Figures 1 and 2). However, in the three patients, non-
digested products of SMNI exons 7 and 8 were not
seen, but only digested products of SMN2 exons 7 and
8 were seen on the gel (Figure 1 and 2). According to
the findings, SMNI exons 7 and 8 were completely
absent, but SMN2 exons 7 and 8 were retained in these
patients. The PCR products of NAIP exon 5 were seen
on the gel for control samples and the Patient 3 but not
for Patients 1 and 2 (Figure 3).
SMNI
SMN2
SMNl
SMN2
digested (i)
SMN2
(diIcsted ji)
Fig. 1: SMN 1 and SMN 2 genes exon 7.
Deletion of exon 7 of SMN 1 gene is seen in Lane 2, 3
and 4.
Lane M: Ladder
Lane 1: Healthy control
Lane 2: Patient 1
Lane 3: Patient 2
Lane 4: Patient 3
Lane 5: peR control (water)
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Fig. 2: SMN 1and SMN 2 genes exon 8.
Deletion of exon 8 of SMN 1 gene is seen in Lane 2, 3
and 4.
Lane M: Ladder
Lane 1: Healthy control
Lane 2: Patient 1
Lane 3: Patient 2
Lane 4: Patient 3
Lane 5: peR control (water)
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